Autolus Therapeutics Plc Share Price

NASDAQ: AUTL

Small Cap

$1.26

-0.06

(-4.17%)

as on September 18, 2025 at 1:29 am IST

$₹

Autolus Therapeutics Plc Stock Performance

as on September 18, 2025 at 1:29 am IST

Day's High
$1.26
Day's Price Range
$1.35
$1.26
7.14%
Upside
52 Week's Low
52 Week's High
$1.11
52-Week Price Range
$5
$1.26
12.30%
Downside
296.83%
Upside

Autolus Therapeutics Plc share price movements today

Previous Close: $1.32
Open: $1.33
Volume: 4.3M
Day's Low - High: $1.26 - $1.35
52 Week Low - High: $1.11 - $5

Autolus Therapeutics Plc Historical Returns

1 Month Return: -25.84 %
3 Month Return: -34.98 %
1 Year Return: -65.62 %
3 Year Return: -47.2 %
5 Year Return: -90.57 %

Autolus Therapeutics Plc Stock Fundamentals & Key Indicators

Check Autolus Therapeutics Plc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$351.3M

EPS (TTM)

-0.8425

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

P/B Ratio

PEG Ratio

EBITDA

-261.3M

Revenue (TTM)

29.9M

Profit Margin

0.00%

Return On Equity TTM

122680500.00%

Autolus Therapeutics Plc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Autolus Therapeutics Plc with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Autolus Therapeutics Plc	BUY	$351.3M	-90.57%	NA	0.00%
Alnylam Pharmaceuticals, Inc.	BUY	$60.5B	252.04%	-505.15	-12.96%
Beone Medicines Ltd	NA	$39.0B	NA	NA	-3.89%
Vertex Pharmaceuticals Incorporated	BUY	$100.3B	44.17%	27.85	31.86%
Regeneron Pharmaceuticals, Inc.	BUY	$59.6B	1.78%	14.1	31.37%

Stock Returns calculator for Autolus Therapeutics Plc Stock including INR - Dollar returns

The Autolus Therapeutics Plc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Autolus Therapeutics Plc investment value today

Current value as on today

₹37,411

Returns

₹62,589

(-62.59%)

Returns from Autolus Therapeutics Plc Stock

₹67,188 (-67.19%)

Dollar Returns*

₹4,598 (+4.6%)

Analyst Recommendation on Autolus Therapeutics Plc Stock

Based on 17 analysts

BUY

82.35%

Buy

17.65%

Hold

0.00%

Sell

Based on 17 analysts, 82.35% of analysts recommend a 'BUY' rating for Autolus Therapeutics Plc. Average target price of $9.62

Autolus Therapeutics Plc Share Price Target

Get share price movements and forecasts by analysts on Autolus Therapeutics Plc.

What analysts predicted

86.9%UPSIDE

Target Price

$9.62

Current Price

$1.26

Analyzed by

17 Analysts

Target

$9.62

Autolus Therapeutics Plc target price $9.62, a slight upside of 86.9% compared to current price of $1.26. According to 17 analysts rating.

Autolus Therapeutics Plc Stock's Interest Amongst Investors

Search interest for Autolus Therapeutics Plc Stock has decreased by -11% in the last 30 days, reflecting a downward trend in search activity.

Time period: August 19, 2025 to September 18, 2025

Change:-11% versus previous 30 day period

Autolus Therapeutics Plc Quarterly Profit & Loss

All numbers in Millions USD

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Total Revenue	1	-	0	1	10	-	-	0	8	20
Gross Profit	0	-1	0	-	8	-1	0	-7	-8	-3
Operating Income	-35	-43	-48	-40	-38	-58	-67	-75	-65	-61
EBITDA	-33	-38	-44	-32	-31	-46	-69	-54	-55	-56
Interest Expense	4	5	5	30	19	10	10	30	10	-
Depreciation	1	1	1	1	1	1	1	2	2	4
Income Before Tax	-43	-49	-50	-64	-52	-58	-82	-26	-67	-47
Income Tax Expense	-3	-3	-4	12	0	0	0	1	2	0
Net Income	-39	-45	-45	-77	-52	-58	-82	-27	-70	-47
Net Profit Margin	-3081.35%	0.00%	-11292.86%	-4347.66%	-522.15%	0.00%	0.00%	-95193.10%	-781.13%	-229.02%

Autolus Therapeutics Plc Annual Profit & Loss

All numbers in Millions USD

	Dec 2019	Sep 2020	Dec 2020	Sep 2021	Dec 2021	Sep 2022	Dec 2022	Sep 2023	Dec 2023	Dec 2024
Total Revenue	2	0	0	2	2	6	6	1	1	10
Gross Profit	-1	-	-134	-	-126	-	-131	-	-4	-1
Operating Income	-137	-	-168	-	-164	-	-163	-	-195	-241
EBITDA	-134	-	-160	-	-132	-	-135	-	-156	-233
Interest Expense	1	-	1	-	1	-	8	-	45	9
Depreciation	4	-	5	-	8	-	7	-	6	7
Income Before Tax	-139	-	-166	-	-165	-	-173	-	-208	-219
Income Tax Expense	-15	-	-24	-	-23	-	-24	-	0	1
Net Income	-123	-142	-142	-142	-142	-148	-148	-208	-208	-220
Net Profit Margin	-4258.91%	-58716.53%	-58716.53%	-6098.54%	-6098.54%	-2402.95%	-2402.95%	-12272.26%	-12272.26%	-2180.45%

Autolus Therapeutics Plc Quarterly Cash Flow

All numbers in Millions USD

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Net Income	-45	-45	-77	-52	-58	-82	-27	-70	-47
Operating Cash Flow	-38	-40	-24	-40	-51	-76	-37	-75	-72
Investing Cash Flow	-4	-1	-1	0	0	-9	-383	-59	95
Financing Cash Flow	0	0	0	561	-2	0	30	-	0
Change in Cash	-35	-50	-17	519	-52	-48	-429	-131	28

Autolus Therapeutics Plc Annual Cash Flow

All numbers in Millions USD

	Dec 2017	Sep 2018	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Net Income	-19	-31	-31	-123	-142	-142	-148	-208	-220
Operating Cash Flow	-16	-25	-25	-101	-117	-117	-112	-145	-206
Investing Cash Flow	-2	-9	-7	-18	-14	-8	-10	-10	-394
Financing Cash Flow	127	117	117	108	74	284	223	0	589
Change in Cash	109	86	86	-6	-57	156	72	-142	-11

Global Institutional Holdings in Autolus Therapeutics Plc

Funds	Holdings
Wellington Management Company LLP	10.18%
Blackstone Inc	7.7%
Deep Track Capital, LP	6.71%
Syncona Portfolio Ltd.	6.25%
Armistice Capital, LLC	4.13%

See all

Insights on Autolus Therapeutics Plc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, -70.16M → -47.91M (in $), with an average increase of 46.4% per quarter
POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 3 quarters, 29.0K → 20.92M (in $), with an average increase of 78.4% per quarter
NO EFFECT
Against Peers
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 116.5% return, outperforming this stock by 163.7%
NO EFFECT
Against Peers
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 68.9% return, outperforming this stock by 134.8%
NEGATIVE IMPACT
Price Dip
In the last 7 days, AUTL stock has moved down by -7.7%

About Autolus Therapeutics Plc

autolus is a private biopharmaceutical company, focused on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. we are building a leading biotechnology company focussed on the development and commercialisation of engineered t-cell therapies for haematological and solid tumours. autolus has the ambition to be a leader of a revolution in medicine in which life-threatening diseases are treated by a patient’s own cells.

Organisation	Autolus Therapeutics Plc
Headquarters	The Mediaworks, London, United Kingdom, W12 7FP
Industry	Health Technology
CEO	Dr. Christian Martin Itin Ph.D.
E-voting on shares	Click here to vote

Key Management of Autolus Therapeutics Plc

Name	Title
Mr. Alex Driggs	Senior VP of Legal Affairs & General Counsel and Secretary
Dr. Martin Pule M.D., MBBS	Founder, Senior VP & Chief Scientific Officer
Mr. Robert F. Dolski	Senior VP, CFO & Principal Accounting Officer
Ms. Olivia Manser	Director of Investor Relations
Mr. Alexander Swan	Senior VP & Chief Human Resources Officer
Dr. Christian Martin Itin Ph.D.	CEO & Director
Dr. Christopher Williams	Chief Business Officer
Dr. Matthias Will M.D.	Senior VP & Chief Development Officer
Mr. Christopher Vann	Senior VP & COO
Mr. David Brochu	Senior VP & Chief Technical Officer

FAQs

What is Autolus Therapeutics Plc share price today?

Autolus Therapeutics Plc share price today is $1.26 as on September 18, 2025 at 1:29 am IST at the close of the market. Autolus Therapeutics Plc share today touched a day high of $1.35 and a low of $1.26.

What is the 52 week high and 52 week low for Autolus Therapeutics Plc share?

Autolus Therapeutics Plc share touched a 52 week high of $5 on October 18, 2024 and a 52 week low of $1.11 on April 11, 2025. Autolus Therapeutics Plc stock price today i.e. September 18, 2025 at 1:29 am IST is closed at $1.26,which is 74.80% down from its 52 week high and 14.03% up from its 52 week low.

What is Autolus Therapeutics Plc's market capitalisation today?

Autolus Therapeutics Plc market capitalisation is $0.00T as on September 18, 2025 at 1:29 am IST.

How to invest in Autolus Therapeutics Plc Stock (AUTL) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Autolus Therapeutics Plc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Autolus Therapeutics Plc Shares that will get you 1.1905 shares as per Autolus Therapeutics Plc share price of $1.26 per share as on September 18, 2025 at 1:29 am IST.

What is the minimum amount required to buy Autolus Therapeutics Plc Stock (AUTL) from India?

Indian investors can start investing in Autolus Therapeutics Plc (AUTL) shares with as little as ₹87.816 or $1 (as of September 18, 2025 at 6:42 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹878.16 in Autolus Therapeutics Plc stock (as per the Rupee-Dollar exchange rate as on September 18, 2025 at 6:42 am IST). Based on Autolus Therapeutics Plc share’s latest price of $1.26 as on September 18, 2025 at 1:29 am IST, you will get 7.9365 shares of Autolus Therapeutics Plc. Learn more about fractional shares .

What are the returns that Autolus Therapeutics Plc has given to Indian investors in the last 5 years?

Autolus Therapeutics Plc stock has given -90.57% share price returns and 20.01% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?